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Introduction. Rheumatoid arthritis (RA) is a polygenic disease associated with accelerated atherosclerosis and increased car-
diovascular (CV) mortality. Recent studies have identified the ABO rs579459, PPAP2B rs17114036, and ADAMTS7 rs3825807
polymorphisms as genetic variants associated with coronary artery disease and the PIK3CG rs17398575 and EDNRA rs1878406
polymorphisms as the most significant signals related to the presence of carotid plaque in nonrheumatic Caucasian individuals.
Accordingly, we evaluated the potential relationship between these 5 polymorphisms and subclinical atherosclerosis (assessed by
carotid intima-media thickness (cIMT) and presence/absence of carotid plaques) and CV disease in RA. Material and Methods.
2140 Spanish RA patients were genotyped for the 5 polymorphisms by TaqMan assays. Subclinical atherosclerosis was evaluated
in 620 of these patients by carotid ultrasonography technology. Results. No statistically significant differences were found when
each polymorphism was assessed according to cIMT values and presence/absence of carotid plaques in RA, after adjusting the
results for potential confounders. Moreover, no significant differences were obtained when RA patients were stratified according to
the presence/absence of CV disease after adjusting for potential confounders. Conclusion. Our results do not confirm association
between ABO rs579459, PPAP2B rs17114036, ADAMTS7 rs3825807, PIK3CG rs17398575, and EDNRA rs1878406 and subclinical
atherosclerosis and CV disease in RA.
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1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease charac-
terized by inflammation of synovial tissues in the joints and
pannus formation and erosion [1]. This pathology affects up
to 1% of the Caucasian population [2] and is associated with
increased risk of cardiovascular (CV) disease and CV death
[3].This is the result of a process of accelerated atherosclerosis
[4]. Although the etiology of RA is still unknown, traditional
CV risk factors, chronic inflammation [5], and genetic back-
ground [6–9] have been implicated in the augmented CV
mortality detected in this disorder. Subclinical atherosclerosis
has been observed in patients with RA [10], even in those
without traditional CV risk factors [10]. In this regard, both
the assessment of carotid intima-media thickness (cIMT) and
the presence of carotid plaques have been proposed to be
useful markers as predictors of CV events in low and inter-
mediate risk groups of nonrheumatic individuals [11] and in
RA patients [12, 13].
Recently, a large-scale study of coronary artery disease
(CAD) performed in nonrheumatic Caucasian individuals
has identified 13 novel loci harboring one or more polymor-
phisms that were associated with this pathology. Moreover,
this study confirmed the association of 10 out of 12 previously
reported CAD loci [14]. With respect to this, the polymor-
phisms ABO (histoblood group ABO system transferase)
rs579459, PPAP2B (phosphatidic acid phosphatase type 2B)
rs17114036, and ADAMTS7 (metallopeptidase with throm-
bospondin type 1 motif, 7) rs3825807 have been identified
as significant genetic variants associated with CAD in non-
rheumatic Caucasian individuals [14]. In addition, a recent
meta-analysis of carotid intima-media thickness (cIMT)
and presence/absence of carotid plaque performed in non-
rheumatic Caucasian individuals has identified five new loci
for common cIMT and plaque [15]. In this regard, the poly-
morphisms PIK3CG (phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit gamma isoform) rs17398575 and
EDNRA (endothelin receptor type A) rs1878406 have been
revealed as the most significant signals associated with pre-
sence of carotid plaques in nonrheumatic Caucasian individ-
uals [15].
Taking all these considerations together, we aimed to
determine, for the first time, the potential association
between the ABO rs579459, PPAP2B rs17114036, ADAMTS7
rs3825807, PIK3CG rs17398575, and EDNRA rs1878406 poly-
morphisms and subclinical atherosclerosis (assessed by the
evaluation of cIMT values and presence/absence of carotid
plaques) and CV disease in a large and well-characterized
cohort of RA patients.
2. Patients and Methods
2.1. Patients and Study Protocol. For this purpose, a set of
2140 Spanish patients with RA were included in the present
study. Blood samples were obtained from patients recruited
from Hospital Lucus Augusti (Lugo), Hospital Marque´s de
Valdecilla (Santander), Hospital de Bellvitge (Barcelona), and
Hospital Cl´ınico San Carlos, Hospital La Paz, Hospital La
Table 1: Demographic and clinical characteristics of the Spanish
patients with RA included in the study.
Clinical feature % (𝑛/𝑁)
Patients 2140
Main characteristics
Age at the time of disease onset
(years, mean ± SD) 52.4 ± 14.9
Follow-up (years, mean ± SD) 12.2 ± 8.8
Percentage of women 75.1
Rheumatoid factor positive∗ 67.9 (1388/2044)
Anti-CCP antibodies positive 59.2 (1058/1786)
Shared epitope positive 62.4 (736/1180)
Erosions 54.7 (940/1718)
Extra-articular manifestations∗∗ 31.5 (540/1715)
Cardiovascular risk factors
Hypertension 38.7 (817/2108)
Diabetes mellitus 12.2 (258/2108)
Dyslipidemia 37.3 (786/2108)
Obesity 16.8 (355/2108)
Smoking habit 23.8 (502/2108)
Patients with cardiovascular events 17.6 (377/2140)
Ischemic heart disease 8.3 (179/2140)
Heart failure 5.3 (113/2140)
Cerebrovascular accident 5.3 (114/2140)
Peripheral arteriopathy 2.3 (50/2140)
RA: rheumatoid arthritis; SD: standard deviation; Anti-CCP antibodies:
anticyclic citrullinated peptide antibodies.
∗At least two determinations were required for analysis of this result.
∗∗Extra-articularmanifestations of the disease (if RA patients experienced at
least one of the following manifestations: nodular disease, Felty’s syndrome,
pulmonary fibrosis, rheumatoid vasculitis, or secondary Sjo¨gren’s syndrome)
[4].
Princesa, Hospital Gregorio Maran˜o´n and Hospital 12 de
Octubre (Madrid). A subject’s written consent was obtained
in all the cases. The Ethics Committees of the corresponding
hospitals approved the purpose of the work. All the patients
fulfilled the 1987 American College of Rheumatology (ACR)
and the 2010 classification criteria for RA [16, 17]. In all
the cases, patients were assessed for ABO rs579459, PPAP2B
rs17114036, ADAMTS7 rs3825807, PIK3CG rs17398575 and
EDNRA rs1878406 polymorphisms. In addition, cIMT and
presence/absence of carotid plaques were determined by
carotid ultrasonography (US) in 620 of these patients.
Information on the main demographic data, clinical
characteristics, CV risk factors, and CV events of patients
enrolled in the study is shown in Table 1. Three hundred and
seventy-seven (17.6%) of these 2140 patients had experienced
CV events. Definitions of CV events and traditional CV risk
factors were established as previously described [4, 13].
2.2. Genotyping. DNA from patients was obtained from
peripheral blood using standard methods.
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The ABO rs579459, PPAP2B rs17114036, ADAMTS7
rs3825807, PIK3CG rs17398575, and EDNRA rs1878406 poly-
morphisms were genotyped with TaqMan predesigned
single-nucleotide polymorphism genotyping assays in a 7900
HT Real-Time polymerase chain reaction (PCR) system,
according to the conditions recommended by the manufac-
turer (Applied Biosystems, Foster City, CA, USA). Negative
controls and duplicate samples were included to check the
accuracy of genotyping.
2.3. Carotid US Examination. Measurement of the cIMT and
presence/absence of carotid plaques were performed in 620
patients from Lugo and Santander by carotid US. Patients
from Santander were assessed using a commercially available
scanner, MyLab 70, Esaote (Genoa, Italy), equipped with 7–
12MHz linear transducer and the automated software-guided
technique radiofrequency—Quality Intima Media Thickness
in real-time (QIMT, Esaote, Maastricht, Holland)—was used
[18]. Patients from Lugo were assessed using high-resolution
B-mode ultrasound, Hewlett Packard SONOS 5500, with a
10-MHz linear transducer as previously reported [19]. cIMT
was measured at the far wall of the right and left common
carotid arteries, 10mm from the carotid bifurcation, over
the proximal 15mm long segment. cIMT was determined
as the average of three measurements in each common
carotid artery. The final cIMT was the largest average
cIMT (left or right). The plaque criteria in the accessible
extracranial carotid tree (common carotid artery, bulb, and
internal carotid artery) were cIMT >1.5mm, protrusion at
least 50% greater than the surrounding cIMT, or arterial
lumen encroaching >0.5mm, according to Mannheim con-
sensus criteria [20]. The carotid plaques were counted in
each territory and defined as no plaque, unilateral plaque, or
bilateral plaques [18, 20–22]. Agreement between the two US
methods in patients with RA was previously reported [21].
Two experts with high experience and close collaboration
in the assessment of subclinical atherosclerosis in RA from
Santander (AC) and Lugo (CGJ) performed the studies.
2.4. Statistical Analysis. Statistical power for CV events
was calculated using CaTS—Power Calculator for Two
Stage Association Studies (http://www.sph.umich.edu/csg/
abecasis/CaTS/). All genotype data were checked for devi-
ation from Hardy-Weinberg equilibrium (HWE) using
http://ihg.gsf.de/cgi-bin/hw/hwa1.pl.
cIMT values are displayed as mean and standard devi-
ation (SD). The association between genotypes and alleles
of each polymorphism and cIMT values was tested using
unpaired 𝑡-test to compare between 2 groups and one-way
analysis of variance (ANOVA) to compare more than two
groups. Comparisons of means were adjusted for sex, age
at the time of US study, follow-up time, and traditional CV
risk factors (hypertension, diabetes mellitus, dyslipidemia,
obesity, and smoking habit) as potential confounders using
analysis of covariance (ANCOVA).
Differences in the genotypic and allelic frequencies of
each polymorphism according to the presence/absence of
carotid plaques were calculated by 𝜒2 or Fisher tests when
necessary (expected values below 5). Strengths of associations
were estimated using odds ratios (OR) and 95% confidence
intervals (CI). Results were adjusted for sex, age at the
time of US study, and traditional CV risk factors by logistic
regression.
The relationship between genotypes and alleles of each
polymorphism and CV events that occurred in the follow-up
was tested using Cox regression adjusted for sex, age at RA
diagnosis, and traditional CV risk factors. For that purpose,
we used the most frequent genotype and allele as reference;
the end of follow-up was the first date among the end of the
study, date of death, or date of CV event. Follow-up time
was estimated as the difference between the RA diagnosis
date and the end of follow-up. Patients without CV events
in the follow-up time or dying by any non-CV cause were
considered as censored. Results were expressed as hazard
ratios (HR) with 95% confidence interval (CI).
Statistical significance was defined as 𝑃 < 0.05. All anal-
yses were performed with STATA statistical software 12/SE
(Stata Corp., College Station, TX, USA).
3. Results
This study had >80% of power to detect genotypic OR >1.4
forABO rs579459,PPAP2B rs17114036,ADAMTS7 rs3825807,
PIK3CG rs17398575, and EDNRA rs1878406.
The ABO rs579459, PPAP2B rs17114036, ADAMTS7
rs3825807, PIK3CG rs17398575, and EDNRA rs1878406 geno-
type distributions were in Hardy-Weinberg equilibrium. The
genotyping success was greater than 97% in all the cases.
Table 2 describes the potential association between the
ABO rs579459, PPAP2B rs17114036, ADAMTS7 rs3825807,
PIK3CG rs17398575, and EDNRA rs1878406 polymorphisms
and both subclinical atherosclerosis and CV disease in
RA patients. As shown in Table 2, no statistically signifi-
cant differences were found when each polymorphism was
assessed according to the evaluation of the cIMT in RA
patients, after adjusting the results for sex, age at the time
of US study, and traditional CV risk factors (hypertension,
diabetes mellitus, dyslipidemia, obesity, and smoking habit)
as potential confounders. Similarly, no statistically significant
differenceswere detectedwhen each polymorphismwas eval-
uated according to the presence/absence of carotid plaques
in RA, after adjusting the results for potential cofounder
factors (Table 2). Moreover, when RA patients were stratified
according to the presence or absence of CV disease, no sig-
nificant differences were obtained after adjusting the results
for sex, age at RA diagnosis, and traditional CV risk factors
(Table 2). It was also the case whenRApatients were stratified
according to the presence/absence of ischemic heart disease
(data not shown).
4. Discussion
CVdisease is themost common cause of prematuremortality
in patients with RA being a consequence of accelerated
atherosclerosis [23]. Since a genetic background [6–9] has
been involved in the accelerated atherosclerosis inRA, several
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Table 2: Association between AB0, PPAP2B, ADAMTS7, PIK3CG, and EDNRA genotypes and alleles and cIMT, presence/absence of carotid
plaques, and CV events in RA patients.
cIMT mm
(𝑛 = 620)
Presence/absence of carotid plaques
(𝑛 = 620)
Presence/absence of CV events
(𝑛 = 2140)
Mean ± SD 𝑃∗ 𝑃∗∗ OR [95% CI]∗∗ 𝑃∗∗∗ HR [95% CI]∗∗∗
ABO rs579459
TT 0.73 ± 0.17 0.91 — 1 (Ref.) — 1 (Ref.)
TC 0.74 ± 0.17 0.23 0.66 [0.33–1.30] 0.79 1.05 [0.72–1.53]
CC 0.71 ± 0.17 0.63 0.71 [0.18–2.86] 0.22 0.59 [0.26–1.37]
T 0.74 ± 0.17 0.86 — 1 (Ref.) — 1 (Ref.)
C 0.73 ± 0.17 0.29 0.76 [0.45–1.26] 0.47 0.89 [0.67–1.20]
PPAP2B rs17114036
AA 0.74 ± 0.17 0.64 — 1 (Ref.) — 1 (Ref.)
AG 0.73 ± 0.19 0.55 1.14 [0.71–1.86] 0.99 0.99 [0.58–1.70]
GG 0.74 ± 0.23 0.10 0.72 [0.03–1.54] ¥ ¥
A 0.74 ± 0.17 0.99 — 1 (Ref.) — 1 (Ref.)
G 0.74 ± 0.19 0.10 0.49 [0.21–1.15] 0.48 0.83 [0.50–1.39]
ADAMTS7 rs3825807
AA 0.76 ± 0.17 0.46 — 1 (Ref.) — 1 (Ref.)
AG 0.73 ± 0.17 0.44 0.86 [0.58–1.28] 0.10 0.59 [0.39–1.20]
GG 0.72 ± 0.17 0.72 0.92 [0.57–1.49] 0.73 0.92 [0.56–1.49]
A 0.74 ± 0.17 0.34 — 1 (Ref.) — 1 (Ref.)
G 0.73 ± 0.17 0.53 0.86 [0.55–1.36] 0.43 0.89 [0.69–1.17]
PIK3CG rs17398575
GG 0.73 ± 0.16 0.1 — 1 (Ref.) — 1 (Ref.)
GA 0.74 ± 0.18 0.34 1.38 [0.72–2.64] 0.99 1.00 [0.68–1.47]
AA 0.75 ± 0.19 0.86 0.86 [0.17–4.26] 0.95 1.02 [0.47–2.23]
G 0.73 ± 0.17 0.09 — 1 (Ref.) — 1 (Ref.)
A 0.74 ± 0.18 0.56 1.17 [0.70–1.95] 0.96 1.00 [0.75–1.36]
EDNRA rs1878406
CC 0.73 ± 0.16 0.61 — 1 (Ref.) — 1 (Ref.)
CT 0.74 ± 0.19 0.28 1.54 [0.70–3.38] 0.44 0.83 [0.53–1.32]
TT 0.73 ± 0.14 0.80 0.76 [0.10–6.04] 0.85 1.10 [0.40–2.90]
C 0.74 ± 0.16 0.32 — 1 (Ref.) — 1 (Ref.)
T 0.74 ± 0.18 0.47 1.28 [0.66–2.47] 0.62 0.91 [0.62–1.33]
cIMT: carotid intima-media thickness; CV: cardiovascular; RA: rheumatoid arthritis; SD: standard deviation; OR: odds ratio; CI: confidence interval; HR:
hazard ratios.
∗Adjusted for sex, age at the time of ultrasonography study, follow-up time, and traditional CV risk factors (hypertension, diabetes mellitus, dyslipidemia,
obesity, and smoking habit) using analysis of covariance (ANCOVA).
∗∗Adjusted for sex, age at the time of ultrasonography study, follow-up time, and traditional CV risk factors (hypertension, diabetes mellitus, dyslipidemia,
obesity, and smoking habit) by logistic regression.
∗∗∗Adjusted for sex, age at RA diagnosis, follow-up time, and traditional CV risk factors (hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking
habit) using Cox regression.
¥Model does not converge.
studies have been focused on the search of genetic markers
that may improve the identification of RA patients at risk of
experiencing CV events.
Previous studies have described the ABO rs579459,
PPAP2B rs17114036, and ADAMTS7 rs3825807 polymorphi-
sms as genetic variants associated with coronary artery dis-
ease [14] and the PIK3CG rs17398575 and EDNRA rs1878406
polymorphisms as the most significant signals related to the
presence of carotid plaque [15] in nonrheumatic Caucasian
individuals. Taking into account these considerations, we
assessed for the first time the potential association between
these 5 polymorphisms and subclinical atherosclerosis and
CV events in RA patients.
Nevertheless, in contrast to the results obtained in
nonrheumatic Caucasian individuals [14], the relationship
between the ABO rs579459, PPAP2B rs17114036, ADAMTS7
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rs3825807, PIK3CG rs17398575, and EDNRA rs1878406 poly-
morphisms and CV events was not statistically significant.
Moreover, unlike nonrheumatic individuals [15], we did not
disclose association between the ABO rs579459, PPAP2B
rs17114036, ADAMTS7 rs3825807, PIK3CG rs17398575, and
EDNRA rs1878406 polymorphisms and cIMT values or pres-
ence/absence of carotid plaques.
Although atherosclerosis and RA are chronic inflamma-
tory diseases that share similar pathophysiological mecha-
nisms [24], additional factors so far unknown may explain
the differences observed in terms of genetic predisposition.
Further studies to better characterize the genetic susceptibil-
ity for accelerated atherosclerosis in RA are under way.
5. Conclusion
Our results do not confirm association of ABO rs579459,
PPAP2B rs17114036, ADAMTS7 rs3825807, PIK3CG
rs17398575, and EDNRA rs1878406 polymorphisms with
subclinical atherosclerosis and CV disease in RA patients.
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